Kura Oncology KURA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Kura Oncology’s reported figures.
Based on trailing twelve months.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's return on equity?
- Kura Oncology (KURA) reported return on equity of -124.7% in Q1 2026.
- How has Kura Oncology's return on equity changed year-over-year?
- Kura Oncology's return on equity decreased by 198.2% year-over-year, from -41.8% to -124.7%.
- What is the long-term trend for Kura Oncology's return on equity?
- Over 5 years (2020 to 2025), Kura Oncology's return on equity has grown at a 34.4% compound annual growth rate (CAGR), from -21.6% to -94.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.